Benlysta Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Benlysta Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report offers insights into Benlysta's uses, sales forecasts, mechanism of action, and potential indications across major global markets, including the U.S., Europe, and Japan. It provides a comprehensive examination of current and future market scenarios, placing emphasis on research, development, and the competitive landscape.
Benlysta (Belimumab) is a recombinant monoclonal antibody for systemic lupus erythematosus (SLE) and lupus nephritis, targeting B-lymphocyte stimulator. Clinical trials demonstrate its efficacy in reducing disease activity and flares, generally well tolerated with common side effects including nausea and fever.
GSK has enhanced production capacity for Benlysta, investing $139 million in its Maryland site as of 2017. These developments underpin the subcutaneous form's support.
Key Factors Driving Benlysta Growth
Strong and Sustained Sales Growth Momentum
First-in-Class BLyS (BAFF) Inhibitor
Expansion into Lupus Nephritis
Shift Toward Subcutaneous Administration
Increasing Adoption of Biologics
Benlysta Recent Developments
Scope of the Benlysta Market Report
Key Questions
For more information about this report visit https://www.researchandmarkets.com/r/tzwzxx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.